Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Norelgestromin,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives Approval for Generic Version of Ortho Evra®
Details : Amneal Pharmaceuticals has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System.
Product Name : Zafemy
Product Type : Hormone
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : Norelgestromin,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norelgestromin,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Gedeon Richter
Deal Size : $263.5 million
Deal Type : Acquisition
Richter Announces the Acquisition of Janssen’s Evra® Transdermal Contraceptive Patch Assets
Details : Evra is a transdermal contraceptive patch assets. The deal is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing autho...
Product Name : Evra
Product Type : Hormone
Upfront Cash : Undisclosed
March 12, 2020
Lead Product(s) : Norelgestromin,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Gedeon Richter
Deal Size : $263.5 million
Deal Type : Acquisition